Although FGFR4 has emerged as a compelling therapeutic target in ARMS due to its overexpression and functional role downstream of PAX3-FOXO1 (see Section 7.2), not all FGFR inhibitors have demonstrated clinical utility in this context. Here, PAX3 is linked to alveolar rhabdomyosarcoma.